Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

被引：0
|
作者：
De La Fuente Burguera, Adolfo [1 ]
Cerchione, Claudio [2 ]
Scholl, Sebastian [3 ]
Middeke, Jan Moritz [4 ,5 ]
Choudhary, Gaurav S. [6 ]
von Roemeling, Reinhard [6 ]
Platzbecker, Uwe [7 ]
机构：
[1] MD Anderson Canc Ctr, Madrid, Spain
[2] IRCCS, Ist Sci Romagnolo Studio Cura Tumori IRST, Meldola, FC, Italy
[3] Jena Univ Hosp, Klin Innere Med 3, Jena, Germany
[4] Tech Univ Dresden, Else Kroner Fresenius Ctr Digital Hlth, Dresden, Germany
[5] Tech Univ Dresden, Dresden, Germany
[6] Curis Inc, Lexington, MA USA
[7] Univ Hosp Leipzig, Dept Hematol, Leipzig, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190125
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma of the head and neck: An open-label, single-arm, phase 1b trial
    Jones, Grace M.
    Isaacs, James
    Kennedy, Lucy Boyce
    Ko, Jennifer
    Vidimos, Allison
    Vij, Alok
    Poblete-Lopez, Christine
    Lucas, Jennifer
    Phoon, Yee Peng
    McEnery-Stonelake, Melissa
    Meine, Jon
    Truong, Thach-Giao
    Funchain, Pauline
    Gastman, Brian
    CANCER RESEARCH, 2024, 84 (06)
  • [32] Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax plus Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC)
    Daver, Naval G.
    Wei, Andrew H.
    Stein, Eytan M.
    DeAngelo, Daniel J.
    Pathak, Dhrubajyoti
    Xu, Yunnan
    Grzesiak, Stephanie
    Venditti, Adriano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S217 - S217
  • [33] Trial in Progress: AARON - an open-label phase I/II study of relatlimab (Anti-LAG-3) with nivolumab (Anti-PD-1) in combination with azacitidine ± venetoclax for the treatment of patients with relapsed/refractory and non-fit patients with newly diagnosed acute myeloid leukemia
    Bucklein, V
    Warm, M.
    K, Spiekermann
    Magno, G.
    Schmidt, C.
    Unterhalt, M.
    Daver, N.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 95 - 96
  • [34] Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
    Alexander, Thomas
    Khaw, Seong Lin
    Rubnitz, Jeffrey E.
    Vear, Susan I.
    Lacayo, Norman James
    Schmidt, Michelle
    Tong, Bo
    Rosenwinkel, Lindsey
    Bensman, Lindsey
    Verdugo, Maria
    Kim, Su Young
    Jabbour, Elias
    Stock, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/ Lymphoma Patients: Single-Arm, Open-Label, Phase I Study
    Shi, Hui
    Hu, Kai
    BLOOD, 2022, 140 : 9480 - 9481
  • [36] Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China
    Kang, Liqing
    Xue, Shengli
    Tang, Xiaowen
    Lou, Xiaoyan
    Qian, Chongsheng
    Gong, Wenjie
    Xu, Mingzhu
    Zhou, Haixia
    Yao, Zhen
    Wang, Wei
    Li, Minghao
    Xu, Nan
    Yu, Zhou
    Chen, Suning
    Qiu, Huiying
    Dai, Haiping
    Xu, Yang
    Wu, Depei
    Yu, Lei
    BLOOD, 2023, 142
  • [37] RESULTS OF A PHASE 1B STUDY OF VENETOCLAX PLUS DECITABINE OR AZACITIDINE IN UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS ≥65 YEARS INELIGIBLE FOR STANDARD INDUCTION THERAPY
    Pollyea, D. A.
    Di Nardo, C.
    Thirman, M.
    Letai, A.
    Wei, A.
    Jonas, B. A.
    Arellano, M.
    Frattini, M.
    Kantarjian, H.
    Chyla, B.
    Zhu, M.
    Potluri, J.
    Humerickhouse, R.
    Mabry, M.
    Konopleva, M.
    Pratz, K.
    HAEMATOLOGICA, 2016, 101 : 44 - 44
  • [38] Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
    Cortes, Jorge
    Perl, Alexander E.
    Dohner, Hartmut
    Kantarjian, Hagop
    Martinelli, Giovanni
    Kovacsovics, Tibor
    Rousselot, Philippe
    Steffen, Bjorn
    Dombret, Herve
    Estey, Elihu
    Strickland, Stephen
    Altman, Jessica K.
    Baldus, Claudia D.
    Burnett, Alan
    Kramer, Alwin
    Russell, Nigel
    Shah, Neil P.
    Smith, Catherine C.
    Wang, Eunice S.
    Ifrah, Norbert
    Gammon, Guy
    Trone, Denise
    Lazzaretto, Deborah
    Levis, Mark
    LANCET ONCOLOGY, 2018, 19 (07): : 889 - 903
  • [39] Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
    Hiroshi Handa
    June-Won Cheong
    Yasushi Onishi
    Hiroatsu Iida
    Yukio Kobayashi
    Hyeoung-Joon Kim
    Tzeon-Jye Chiou
    Koji Izutsu
    Olga Tsukurov
    Xiaofei Zhou
    Helene Faessel
    Ying Yuan
    Farhad Sedarati
    Douglas V. Faller
    Akiko Kimura
    Shang-Ju Wu
    Journal of Hematology & Oncology, 15
  • [40] An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia
    Patton, William Nigel
    Lindeman, Robert
    Butler, Andrew C.
    Kipps, Thomas J.
    Jewell, Roxanne C.
    Laubscher, Kevin H.
    Zhou, Yan Yan
    Lewis, Eric
    Sedoti, Donna
    Witman, Philip
    Fang, Lei
    Chan, Geoffrey
    LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2819 - 2825
12345